CSIMarket
 
Agenus Inc  (AGEN)
Other Ticker:  
 
 
Price: $0.5400 $-0.06 -9.955%
Day's High: $0.6101 Week Perf: -19.81 %
Day's Low: $ 0.54 30 Day Perf: -41.8 %
Volume (M): 11,557 52 Wk High: $ 2.13
Volume (M$): $ 6,241 52 Wk Avg: $1.17
Open: $0.61 52 Wk Low: $0.53



 Market Capitalization (Millions $) 210
 Shares Outstanding (Millions) 389
 Employees -
 Revenues (TTM) (Millions $) 101
 Net Income (TTM) (Millions $) -283
 Cash Flow (TTM) (Millions $) -71
 Capital Exp. (TTM) (Millions $) 10

Agenus Inc
Agenus Inc. is a biotechnology company based in Lexington, Massachusetts. The company is focused on the discovery, development, and commercialization of immune-based therapies for the treatment of cancer and other diseases. Agenus utilizes its proprietary technologies to develop novel antibodies, vaccines, and adjuvants to activate the immune system against cancer cells. The company's product pipeline includes both clinical and pre-clinical stage candidates targeting various types of cancer. Agenus also collaborates with other pharmaceutical companies to advance its immunotherapy programs.


   Company Address: 3 Forbes Road Lexington 2421 MA
   Company Phone Number: 674-4400   Stock Exchange / Ticker: NASDAQ AGEN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Agenus Inc

Agenus Inc Shines Bright: Impressive Revenue Surge Witnessed in Q3 2023

The stock market continues to be a place of excitement and opportunity, with recent news from Agenus Inc adding to the positive sentiment. Agenus, a thriving player in the Biotechnology & Pharmaceuticals industries, has shown exceptional performance during the third quarter of the 2023 earnings season.
Breaking it down, Agenus managed to decrease its loss per share from $-0.19 to $-0.16, showcasing a noticeable improvement compared to the previous year. Furthermore, there was a significant increase in earnings per share from $-0.20 in the preceding quarter, highlighting the company's dedication to growth and success.

Agenus Inc

Agenus Inc Shatters Industry Norms with 20.883% Revenue Surge Amidst Market Downturn

Agenus Inc - Revenue Surges Despite Industry Downturn
Agenus Inc, a biotechnology and pharmaceuticals company, recently announced a significant surge in revenue for the fiscal period ending on June 30, 2023. Despite the challenging market conditions faced by the broader biotechnology and pharmaceuticals industry, Agenus managed to achieve a revenue growth of 20.883% to reach $25.30 million, compared to the same reporting period last year.
This growth in revenue is a promising development for Agenus, especially considering that many of its industry peers experienced a decline in their top-line figures during the same period. This contrasting performance by Agenus suggests that the company has a unique approach or strategy that sets it apart from its competitors.

Agenus Inc

Agenus Inc Struggles to Weather Challenging Fiscal Quarter, Accumulates $251 Million Net Loss

Agenus Inc is a biotechnology company that focuses on developing immuno-oncology therapeutics to treat cancer. Despite the company's strong focus on innovation, the latest financial report shows that Agenus Inc has struggled to deliver robust financial results. The company's cumulative net loss of $-251 million during the first quarter of 2023 highlights the significant financial challenges that it has faced in recent times.
One of the most critical performance indicators for companies is the return on investment (ROI), which measures the profitability of investments made by the company. The ROI of Agenus Inc currently stands at -431.94%, which indicates that the company's investments have been unprofitable. Among the 881 companies in the healthcare sector, Agenus Inc is placed at a lower rank in terms of ROI, indicating that the company has not been performing well in comparison to its peers.






 

Agenus Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com